Shopping Cart
Remove All
Your shopping cart is currently empty
Ar-V7-IN-1 (compound 47) is a potent inhibitor of Ar-V7, a genetic mRNA splice variant of the androgen receptor (AR) associated with resistance to AR-targeted therapy in patients with desmoplasia-resistant prostate cancer (mCRPC).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $767 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $997 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $1,740 | 6-8 weeks | 6-8 weeks |
| Description | Ar-V7-IN-1 (compound 47) is a potent inhibitor of Ar-V7, a genetic mRNA splice variant of the androgen receptor (AR) associated with resistance to AR-targeted therapy in patients with desmoplasia-resistant prostate cancer (mCRPC). |
| Molecular Weight | 394.09 |
| Formula | C10H10Br2N4OS |
| Cas No. | 2230880-25-6 |
| Smiles | BrC=1N=CN(C1Br)C=2N=C(SC2)N3CCOCC3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (203 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.37 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.